132.59
price up icon1.23%   1.61
after-market After Hours: 132.52 -0.07 -0.05%
loading
Biogen Inc stock is traded at $132.59, with a volume of 1.23M. It is up +1.23% in the last 24 hours and up +4.97% over the past month. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$130.98
Open:
$130.78
24h Volume:
1.23M
Relative Volume:
0.85
Market Cap:
$19.43B
Revenue:
$9.82B
Net Income/Loss:
$1.48B
P/E Ratio:
13.09
EPS:
10.13
Net Cash Flow:
$2.30B
1W Performance:
+3.03%
1M Performance:
+4.97%
6M Performance:
-9.31%
1Y Performance:
-41.34%
1-Day Range:
Value
$130.00
$132.65
1-Week Range:
Value
$121.05
$132.65
52-Week Range:
Value
$110.03
$236.48

Biogen Inc Stock (BIIB) Company Profile

Name
Name
Biogen Inc
Name
Phone
(781) 464-2000
Name
Address
225 BINNEY STREET, CAMBRIDGE, MA
Name
Employee
7,605
Name
Twitter
@biogen
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
BIIB's Discussions on Twitter

Compare BIIB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
BIIB
Biogen Inc
132.59 19.19B 9.82B 1.48B 2.30B 10.13
Drug Manufacturers - General icon
LLY
Lilly Eli Co
805.43 717.19B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
169.56 404.05B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.83 330.51B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.46 228.37B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
70.73 311.17B 43.59B 15.04B 10.74B 3.3766

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-21-25 Resumed Truist Hold
Apr-28-25 Downgrade HSBC Securities Buy → Hold
Apr-04-25 Downgrade Argus Buy → Hold
Feb-11-25 Initiated Bernstein Mkt Perform
Jan-02-25 Downgrade Piper Sandler Overweight → Neutral
Dec-20-24 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-16-24 Downgrade Stifel Buy → Hold
Dec-10-24 Resumed BofA Securities Neutral
Dec-09-24 Downgrade Jefferies Buy → Hold
Nov-18-24 Downgrade Needham Buy → Hold
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-14-24 Initiated Citigroup Neutral
Oct-31-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-10-24 Resumed Raymond James Mkt Perform
Feb-14-24 Reiterated Needham Buy
Feb-14-24 Downgrade Wells Fargo Overweight → Equal Weight
Jan-24-24 Downgrade UBS Buy → Neutral
Dec-20-23 Resumed Cantor Fitzgerald Overweight
Dec-07-23 Upgrade Raymond James Mkt Perform → Outperform
Sep-06-23 Initiated HSBC Securities Buy
Jul-27-23 Initiated Scotiabank Sector Outperform
Jul-24-23 Reiterated UBS Buy
May-01-23 Upgrade Guggenheim Neutral → Buy
Apr-17-23 Upgrade Piper Sandler Neutral → Overweight
Oct-26-22 Upgrade Goldman Neutral → Buy
Oct-13-22 Upgrade Stifel Hold → Buy
Oct-07-22 Upgrade Argus Hold → Buy
Sep-28-22 Upgrade BMO Capital Markets Market Perform → Outperform
Sep-28-22 Upgrade Mizuho Neutral → Buy
Sep-28-22 Upgrade Robert W. Baird Neutral → Outperform
Apr-18-22 Upgrade Wells Fargo Equal Weight → Overweight
Mar-08-22 Downgrade Stifel Buy → Hold
Mar-03-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-04-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-04-22 Reiterated Barclays Equal Weight
Feb-04-22 Reiterated BofA Securities Neutral
Feb-04-22 Reiterated Cowen Outperform
Feb-04-22 Reiterated Morgan Stanley Overweight
Feb-04-22 Reiterated Needham Buy
Feb-04-22 Reiterated Oppenheimer Outperform
Feb-04-22 Reiterated RBC Capital Mkts Sector Perform
Feb-04-22 Reiterated Robert W. Baird Neutral
Feb-04-22 Reiterated Wedbush Neutral
Feb-04-22 Reiterated Wells Fargo Equal Weight
Feb-04-22 Reiterated Wolfe Research Peer Perform
Jan-13-22 Downgrade Guggenheim Buy → Neutral
Jan-12-22 Downgrade Piper Sandler Overweight → Neutral
Dec-10-21 Resumed Raymond James Mkt Perform
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Initiated BMO Capital Markets Outperform
Sep-23-21 Initiated Needham Buy
Jun-18-21 Upgrade Piper Sandler Neutral → Overweight
Jun-14-21 Reiterated Truist Buy
Jun-11-21 Upgrade Bernstein Mkt Perform → Outperform
Jun-10-21 Upgrade UBS Neutral → Buy
Jun-08-21 Upgrade Atlantic Equities Underweight → Neutral
Jun-08-21 Reiterated Barclays Equal Weight
Jun-08-21 Upgrade Citigroup Sell → Neutral
Jun-08-21 Reiterated H.C. Wainwright Buy
Jun-08-21 Reiterated Jefferies Buy
Jun-08-21 Reiterated Morgan Stanley Overweight
Jun-08-21 Reiterated RBC Capital Mkts Sector Perform
Jun-08-21 Upgrade Robert W. Baird Underperform → Neutral
Jun-08-21 Reiterated Stifel Buy
Jun-08-21 Upgrade William Blair Mkt Perform → Outperform
Jun-07-21 Upgrade BofA Securities Underperform → Neutral
Jun-07-21 Upgrade Cowen Market Perform → Outperform
Jun-07-21 Upgrade Raymond James Underperform → Mkt Perform
Feb-05-21 Downgrade DZ Bank Buy → Hold
Jan-29-21 Upgrade Stifel Hold → Buy
Nov-10-20 Upgrade DZ Bank Hold → Buy
Nov-09-20 Downgrade Atlantic Equities Neutral → Underweight
Nov-09-20 Downgrade BofA Securities Neutral → Underperform
Nov-09-20 Downgrade Cowen Outperform → Market Perform
Nov-09-20 Reiterated H.C. Wainwright Buy
Nov-04-20 Upgrade BofA Securities Underperform → Neutral
Nov-04-20 Upgrade Jefferies Hold → Buy
Nov-04-20 Upgrade Wells Fargo Equal Weight → Overweight
Oct-28-20 Initiated UBS Neutral
Jul-27-20 Upgrade Morgan Stanley Underweight → Overweight
Jun-22-20 Downgrade Barclays Overweight → Equal Weight
Jun-22-20 Reiterated RBC Capital Mkts Sector Perform
Jun-09-20 Downgrade Bernstein Outperform → Mkt Perform
Apr-23-20 Downgrade Citigroup Neutral → Sell
Apr-23-20 Downgrade Raymond James Mkt Perform → Underperform
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-27-20 Upgrade Canaccord Genuity Hold → Buy
Dec-13-19 Upgrade Credit Suisse Underperform → Neutral
Dec-02-19 Downgrade Robert W. Baird Neutral → Underperform
View All

Biogen Inc Stock (BIIB) Latest News

pulisher
Jul 24, 2025

Is Biogen Inc. a good long term investmentFree Buy/Sell Signal Notifications - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Genentech Seeks Win After $122M Biogen Royalties Mistrial - Law360

Jul 24, 2025
pulisher
Jul 24, 2025

Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Recipients - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Biogen, Zydus Settle Patent Suit Over Copies of MS Drug Vumerity - Bloomberg Law News

Jul 24, 2025
pulisher
Jul 24, 2025

Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

Universal Beteiligungs und Servicegesellschaft mbH Has $21.55 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 24, 2025
pulisher
Jul 23, 2025

Biogen Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen to invest $2 billion in RTP, open new factory in 2025 - WRAL.com

Jul 23, 2025
pulisher
Jul 23, 2025

(BIIB) On The My Stocks Page - news.stocktradersdaily.com

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Rep. Robert Bresnahan, Jr. Buys Biogen Inc. (NASDAQ:BIIB) Shares - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

How the Recombinant Dna Technology Market Will Evolve by 2032 - openPR.com

Jul 23, 2025
pulisher
Jul 23, 2025

KLP Kapitalforvaltning AS Purchases 63,700 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

Envestnet Asset Management Inc. Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

Biogen Inc. (NASDAQ:BIIB) Stake Raised by Victory Capital Management Inc. - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

Will Major North Carolina Expansion Change Biogen's (BIIB) Narrative? - simplywall.st

Jul 23, 2025
pulisher
Jul 22, 2025

Beacon Investment Advisory Services Inc. Sells 3,529 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division - Benzinga

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen, one of the largest employers in RTP, plans $2B investment in the Triangle - Axios

Jul 22, 2025
pulisher
Jul 22, 2025

How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Allianz Asset Management GmbH Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

Los Angeles Capital Management LLC Takes $5.93 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

Spinal Muscular Atrophy Treatment Market Growth Accelerated - openPR.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Biogen Inc. stock pricePowerful growth strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen: Hold Rating Amid Stagnant Growth and Uncertain Prospects - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Biogen to invest further $2bn in North Carolina’s Research Triangle Park - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance Biotherapeutics shares rise 2.41% premarket after Biogen's $2 billion investment in North Carolina manufacturing. - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Biogen Inc. stockFree Predictions - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Biogen investing $2B to expand operations in RTP - ABC11

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen's Alzheimer's Innovation Pipeline: Lecanemab and BIIB080 as Catalysts for Long-Term Growth - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - yahoo.co

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - Biogen

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Breakthrough: 48-Month LEQEMBI Results Plus Game-Changing Subcutaneous Alzheimer's Treatment Option - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest $2 billion in RTP facility - CBS 17

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Inc. Invests $2B In North Carolina Expansion - Business Facilities

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Inc. Announces $2 Billion Expansion in North Carolina's Research Triangle Park Amid U.S. Manufacturing Push - Hoodline

Jul 21, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen (BIIB) Stock Trades Down, Here Is Why - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Bets Big On $2 Billion Expansion To Boost US Drug ManufacturingBiogen (NASDAQ:BIIB) - Benzinga

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen invests $2B in U.S. manufacturing — but not in Massachusetts - The Business Journals

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest $2 billion in Research Triangle Park facilities - CBS 17

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen’s Pediatric RRMS Study Completion: Market Implications and Insights - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen (NASDAQ:BIIB) Coverage Initiated by Analysts at Truist Financial - MarketBeat

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen Invests $20 Billion in North Carolina to Counter 200% Tariff Threat - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen to invest further $2 billion in North Carolina facilities - The Pharma Letter

Jul 21, 2025
pulisher
Jul 21, 2025

Biogen beefs up North Carolina manufacturing ahead of potential drug tariff storm - Reuters

Jul 21, 2025
pulisher
Jul 21, 2025

Drugmaker Biogen to invest $2 billion more in North Carolina - 104.1 WIKY

Jul 21, 2025
pulisher
Jul 21, 2025

Truist downgrades Biogen, citing growth challenges, limited pipeline upside - TradingView

Jul 21, 2025

Biogen Inc Stock (BIIB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general SNY
$50.13
price down icon 0.06%
$113.20
price down icon 0.32%
drug_manufacturers_general PFE
$25.35
price down icon 0.04%
$308.55
price down icon 0.22%
drug_manufacturers_general MRK
$84.11
price up icon 0.15%
drug_manufacturers_general NVO
$70.73
price up icon 1.00%
Cap:     |  Volume (24h):